114 related articles for article (PubMed ID: 7053826)
41. Comparison of multiple in vivo and in vitro parameters in untreated patients with Hodgkin's disease.
Case DC; Hansen JA; Corrales E; Young CW; Dupont B; Pinsky CM; Good RA
Cancer; 1976 Oct; 38(4):1807-15. PubMed ID: 1086708
[TBL] [Abstract][Full Text] [Related]
42. Lack of correlation between skin reactivity and T lymphocytes and monocytes in Hodgkin's disease.
Müftüoğlu AU; Yalçin B
Acta Haematol; 1980; 63(5):286-8. PubMed ID: 6774558
[TBL] [Abstract][Full Text] [Related]
43. [Persisting deficiency of cell mediated immunity in Hodgkin's disease in complete remission (author's transl)].
Lang JM; Bigel P; Giron C; Faradji A; Oberling F; Mayer S
Nouv Presse Med; 1979 Nov; 8(44):3629-32. PubMed ID: 316521
[TBL] [Abstract][Full Text] [Related]
44. Effect of levamisole, thymic humoral factor and indomethacin on e-rosette formation of lymphocytes in Hodgkin's disease.
Ramot B; Rosenthal E; Biniaminov M; Ben-Bassat I
Isr J Med Sci; 1981 Apr; 17(4):232-5. PubMed ID: 7195385
[TBL] [Abstract][Full Text] [Related]
45. The effect of thymosin on human T-cells from cancer patients.
Hardy MA; Dattner AM; Sarkar DK; Stoffer JA; Friedmann N
Cancer; 1976 Jan; 37(1):98-103. PubMed ID: 1082366
[TBL] [Abstract][Full Text] [Related]
46. The effect of levamisole on peripheral T-lymphocytes of patients with malignant lymphomas.
Sansoni P; Rossetti A; Tridente G; Butturini U
J Immunopharmacol; 1982-1983; 4(3):223-32. PubMed ID: 6985219
[TBL] [Abstract][Full Text] [Related]
47. Lymphocyte function in patients with Hodgkin's disease.
Rühl H; Vogt W; Rühl U
G Batteriol Virol Immunol; 1975; 68(1-6):3-16. PubMed ID: 128484
[TBL] [Abstract][Full Text] [Related]
48. Immunorestorative properties of thymostimulin (TS) in patients with Hodgkin's disease in clinical remission.
Liberati AM; Brugia M; Edwards BS; Bertoni P; Ballatori E; Puxeddu A; Grignani F
Cancer Immunol Immunother; 1985; 19(2):136-41. PubMed ID: 3872709
[TBL] [Abstract][Full Text] [Related]
49. Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease.
Fisher RI; DeVita VT; Bostick F; Vanhaelen C; Howser DM; Hubbard SM; Young RC
Ann Intern Med; 1980 May; 92(5):595-9. PubMed ID: 6992672
[TBL] [Abstract][Full Text] [Related]
50. [Effect of thymus hormones on the capacity of lymphocytes for contact interaction with mast cells].
Nikol'skiĭ IS; Maevskaia LP; Ovsienko VV
Probl Endokrinol (Mosk); 1988; 34(2):72-4. PubMed ID: 3393508
[TBL] [Abstract][Full Text] [Related]
51. Autologous rosette-forming capacity of T-lymphocytes in Hodgkin's disease.
Bodolay E; Berényi E; Sonkoly I; Szegedi G
Acta Med Hung; 1984; 41(2-3):113-9. PubMed ID: 6611543
[TBL] [Abstract][Full Text] [Related]
52. Zinc status and cellular immunity in pediatric Hodgkin's disease.
Cavdar AO; Babacan E; Ertem U; Gözdasoğlu S; Arcasoy A
Prog Clin Biol Res; 1983; 129():207-20. PubMed ID: 6657703
[TBL] [Abstract][Full Text] [Related]
53. Thymic hormone dependent immunodeficiency in an infant with partial trisomy of chromosome 22.
Tovo PA; Davi G; Fraceschini P; Delpiano A
Thymus; 1986; 8(5):313-8. PubMed ID: 3798528
[TBL] [Abstract][Full Text] [Related]
54. The influence of splenectomy on the invitro lymphocyte response to phytohemagglutinin and pokeweed mitogen in Hodgkin's disease.
Wagener DJ; Geestman E; Wessels HM
Cancer; 1975 Jul; 36(1):194-8. PubMed ID: 1203846
[TBL] [Abstract][Full Text] [Related]
55. Immune deficiency in Hodgkin and non-Hodgkin lymphoma.
El-Haddad SI; El-Ashmawy S; Hassan W; George E; Ali FM; Sharaf MA; Mahfouz M
Biomedicine; 1980 Oct; 32(3):128-33. PubMed ID: 7448322
[TBL] [Abstract][Full Text] [Related]
56. Rosette and blastogenesis inhibition by plasma from Hodgkin's disease and other malignancies. Positive correlation in State I and II Hodgkin's disease.
Sinclair T; Ezdinli EZ; Boonlayangoor P; Wasser LP; Han T
Cancer; 1983 Jan; 51(2):238-44. PubMed ID: 6336976
[TBL] [Abstract][Full Text] [Related]
57. Effects of radiochemotherapy and splenectomy on cellular immunity in long-term survivors of Hodgkin's disease and non-Hodgkin's lymphoma.
Steele R; Han T
Cancer; 1978 Jul; 42(1):133-9. PubMed ID: 667791
[TBL] [Abstract][Full Text] [Related]
58. Monocyte PGE2 secretion in Hodgkin's disease and its relation to decreased cellular immunity.
Passwell J; Levanon M; Davidsohn J; Ramot B
Clin Exp Immunol; 1983 Jan; 51(1):61-8. PubMed ID: 6572580
[TBL] [Abstract][Full Text] [Related]
59. Immunological capacity of lymphocytes from untreated patients with Hodgkin's disease evaluated in mixed lymphocyte culture.
Björkholm M; Holm G; Mellstedt H; Pettersson D
Clin Exp Immunol; 1975 Dec; 22(3):373-7. PubMed ID: 131665
[TBL] [Abstract][Full Text] [Related]
60. Serum zinc levels, lymphocyte counts and functions in pediatric Hodgkin's disease.
Babacan E; Cavdar AO; Arcasoy A
Boll Ist Sieroter Milan; 1977 Jul; 56(3):228-34. PubMed ID: 901636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
